Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBITDA (2022 - 2025)

CervoMed's EBITDA history spans 9 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, EBITDA fell 67.44% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$25.7 million, down 117.37%, while the annual FY2024 figure was -$16.2 million, 647.49% down from the prior year.
  • EBITDA for Q3 2025 was -$7.7 million at CervoMed, down from -$6.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $2.2 million in Q3 2023 and bottomed at -$7.7 million in Q3 2025.
  • The 4-year median for EBITDA is -$4.1 million (2023), against an average of -$3.8 million.
  • The largest annual shift saw EBITDA soared 176.83% in 2023 before it crashed 314.41% in 2024.
  • A 4-year view of EBITDA shows it stood at -$4.0 million in 2022, then skyrocketed by 41.3% to -$2.4 million in 2023, then plummeted by 186.7% to -$6.8 million in 2024, then dropped by 13.98% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's EBITDA are -$7.7 million (Q3 2025), -$6.3 million (Q2 2025), and -$4.9 million (Q1 2025).